Australian Clinical Labs (ASX:ACL) - Aandelenkoers, Nieuws & Analyse

ACL Overzicht aandelen

Australian Clinical Labs Limited biedt diagnostische pathologiediensten aan in Australië. Meer informatie

ACL fundamentele analyse
Sneeuwvlok Score
Waardering	3/6
Toekomstige groei	3/6
Prestaties in het verleden	1/6
Financiële gezondheid	4/6
Dividenden	2/6

Beloningen

Verhandeld tegen 41.7% onder onze schatting van de reële waarde

De winst zal naar verwachting met 15.98% per jaar groeien

Risicoanalyse

Grote eenmalige posten die de financiële resultaten beïnvloeden

Dividend van 3.46% wordt niet goed gedekt door de winst

Winstmarges (3.4%) zijn lager dan vorig jaar (5.2%)

Australian Clinical Labs Limited Concurrenten

Healthia

ASX:HLA

AU$252.1m

SILK Laser Australia

ASX:SLA

AU$177.4m

Apiam Animal Health

ASX:AHX

AU$84.0m

Sonic Healthcare

ASX:SHL

AU$13.3b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Australian Clinical Labs
Historische aandelenkoersen
Huidige aandelenkoers	AU$3.47
52 Week Hoogtepunt	AU$3.86
52 Week Laag	AU$2.14
Bèta	1.15
11 maand verandering	-3.88%
3 maanden verandering	22.61%
1 Jaar Verandering	35.55%
33 jaar verandering	-17.97%
5 jaar verandering	n/a
Verandering sinds IPO	1.46%

Recent nieuws en updates

Why Investors Shouldn't Be Surprised By Australian Clinical Labs Limited's (ASX:ACL) 29% Share Price Surge

Sep 03

Should You Think About Buying Australian Clinical Labs Limited (ASX:ACL) Now?

Sep 02

Recent updates

Why Investors Shouldn't Be Surprised By Australian Clinical Labs Limited's (ASX:ACL) 29% Share Price Surge

Sep 03

Here's Why We Think Australian Clinical Labs (ASX:ACL) Might Deserve Your Attention Today

Aug 14

Australian Clinical Labs Limited (ASX:ACL) Just Reported Half-Year Earnings: Have Analysts Changed Their Mind On The Stock?

Feb 25

New Forecasts: Here's What Analysts Think The Future Holds For Australian Clinical Labs Limited (ASX:ACL)

Dec 22

The Market Lifts Australian Clinical Labs Limited (ASX:ACL) Shares 31% But It Can Do More

Dec 21

The Strong Earnings Posted By Australian Clinical Labs (ASX:ACL) Are A Good Indication Of The Strength Of The Business

Sep 01

Rendement voor aandeelhouders

	ACL	AU Healthcare	AU Markt
7D	-2.0%	0.7%	1.5%
1Y	35.5%	4.0%	17.2%

Rendement versus industrie: ACL overtrof de Australian Healthcare industrie, die het afgelopen jaar een rendement 4 % opleverde.

Rendement versus markt: ACL overtrof de Australian markt, die het afgelopen jaar een rendement opleverde van 17.2 %.

Prijsvolatiliteit

Is ACL's price volatile compared to industry and market?
ACL volatility
ACL Average Weekly Movement	5.0%
Healthcare Industry Average Movement	5.1%
Market Average Movement	8.6%
10% most volatile stocks in AU Market	17.3%
10% least volatile stocks in AU Market	3.4%

Stabiele aandelenkoers: ACL heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 5% ) van ACL is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2020	4,900	Melinda McGrath	www.clinicallabs.com.au

Australian Clinical Labs Limited biedt diagnostische pathologiediensten aan in Australië. Het bedrijf biedt een reeks diensten aan, waaronder routinematige pathologietests, geavanceerde moleculaire genetische tests, harmonie NIPT en screening van het eerste trimester, screening van genetische dragers, chemische pathologie, histopathologie en cytopathologie; hematologie, allergie en immunologie; serologie en microbiologie; en infectieuze moleculaire tests, cardiale testdiensten, functionele pathologie, veterinaire pathologie en commerciële drugs- en alcoholtestdiensten. Het biedt zijn diensten aan privé- en openbare ziekenhuizen aan.

Australian Clinical Labs Limited Samenvatting

Hoe verhouden de winst en inkomsten van Australian Clinical Labs zich tot de beurswaarde?
ACL fundamentele statistieken
Marktkapitalisatie	AU$682.41m
Inkomsten(TTM)	AU$23.93m
Inkomsten(TTM)	AU$696.37m

28.9x

Koers/Winstverhouding

1.0x

P/S-verhouding

Is ACL overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ACL resultatenrekening (TTM)
Inkomsten	AU$696.37m
Kosten van inkomsten	AU$442.37m
Brutowinst	AU$254.00m
Overige uitgaven	AU$230.07m
Inkomsten	AU$23.93m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

Feb 26, 2025

Winst per aandeel (EPS)	0.12
Brutomarge	36.48%
Nettowinstmarge	3.44%
Schuld/Eigen Vermogen Verhouding	31.0%

Hoe presteerde ACL op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

3.5%

Huidig dividendrendement

100%

Uitbetalingsratio

ACL Overzicht aandelen

Beloningen

Risicoanalyse

Australian Clinical Labs Limited Concurrenten

ASX:HLA

AU$252.1m

ASX:SLA

AU$177.4m

ASX:AHX

AU$84.0m

ASX:SHL

AU$13.3b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Australian Clinical Labs Limited to Report Fiscal Year 2025 Results on Aug 26, 2025

Investor sentiment improves as stock rises 25%

Why Investors Shouldn't Be Surprised By Australian Clinical Labs Limited's (ASX:ACL) 29% Share Price Surge

Should You Think About Buying Australian Clinical Labs Limited (ASX:ACL) Now?

Final dividend of AU$0.09 announced

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

Australian Clinical Labs Limited to Report Fiscal Year 2025 Results on Aug 26, 2025

Investor sentiment improves as stock rises 25%

Why Investors Shouldn't Be Surprised By Australian Clinical Labs Limited's (ASX:ACL) 29% Share Price Surge

Should You Think About Buying Australian Clinical Labs Limited (ASX:ACL) Now?

Final dividend of AU$0.09 announced

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Australian Clinical Labs Limited Provides Financial Guidance for the Fiscal Year 2025

Australian Clinical Labs Limited to Report Fiscal Year 2024 Results on Aug 29, 2024

Australian Clinical Labs Limited, Annual General Meeting, Oct 25, 2024

We Think Australian Clinical Labs (ASX:ACL) Is Taking Some Risk With Its Debt

Upcoming dividend of AU$0.03 per share

Consensus EPS estimates fall by 20%

First half dividend reduced to AU$0.03

First half 2024 earnings released: EPS: AU$0.025 (vs AU$0.13 in 1H 2023)

Are Investors Undervaluing Australian Clinical Labs Limited (ASX:ACL) By 46%?

Australian Clinical Labs Limited to Report First Half, 2024 Results on Feb 28, 2024

Is It Time To Consider Buying Australian Clinical Labs Limited (ASX:ACL)?

Price target decreased by 7.5% to AU$3.56

Upcoming dividend of AU$0.07 per share at 4.6% yield

Consensus EPS estimates fall by 21%

Australian Clinical Labs Limited Announces Appointment of Christine Bartlett as Non-Executive Director

Australian Clinical Labs Limited Declares Full Year Fully Franked Dividend for the Fiscal Year 2023, Payable on 3 October 2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of AU$0.07 per share at 13% yield

Price target increased by 7.1% to AU$4.03

First half 2023 earnings released: EPS: AU$0.13 (vs AU$0.65 in 1H 2022)

Australian Clinical Labs Limited Announces Dividend for the Six Months Ended December 31, 2022, Payable on April 26, 2023

Investor sentiment improves as stock rises 16%

Price target decreased by 8.5% to AU$3.76

Price target decreased to AU$4.27

High number of new and inexperienced directors

Price target decreased to AU$4.62

Independent Non-Executive Director recently sold AU$71k worth of stock

Australian Clinical Labs Limited Announces Resignation of Dr. Michael Stanford as Non-Executive Director

Australian Clinical Labs Limited, Annual General Meeting, Oct 25, 2023

Independent Non-Executive Director recently sold AU$140k worth of stock

Upcoming dividend of AU$0.41 per share

Here's Why We Think Australian Clinical Labs (ASX:ACL) Might Deserve Your Attention Today

Full year 2022 earnings: EPS misses analyst expectations

Price target decreased to AU$5.30

Australian Clinical Labs Limited Declares Dividend for the Period of Six Months Ended 30 June 2022

Investor sentiment deteriorated over the past week

CEO & Executive Director recently bought AU$335k worth of stock

High number of new and inexperienced directors

First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Australian Clinical Labs Limited Declares Ordinary Dividend for the Period of Six Months December 31, 2021, Payable April 21, 2022

Australian Clinical Labs Limited (ASX:ACL) Just Reported Half-Year Earnings: Have Analysts Changed Their Mind On The Stock?

Australian Clinical Labs Limited Revises Earnings Guidance for the First Half 2022

New Forecasts: Here's What Analysts Think The Future Holds For Australian Clinical Labs Limited (ASX:ACL)

The Market Lifts Australian Clinical Labs Limited (ASX:ACL) Shares 31% But It Can Do More

Investor sentiment improved over the past week

Consensus EPS estimates increase by 46%

Australian Clinical Labs Limited (ASX:ACL) completed the acquisition of Medlab Pathology Pty Ltd.

Independent Non-Executive Director recently bought AU$99k worth of stock

The Strong Earnings Posted By Australian Clinical Labs (ASX:ACL) Are A Good Indication Of The Strength Of The Business

Full year 2021 earnings released: EPS AU$0.40 (vs AU$0.28 in FY 2020)

Australian Clinical Labs Limited Provides Earnings Guidance for the Fiscal Year of 2021

Australian Clinical Labs Limited has completed an IPO in the amount of AUD 408.559209 million.

Rendement voor aandeelhouders